Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Sai Life Sciences
Mid Cap•3,401 Employees•IPO 2024
Current Price
₹996.35
-1.9 (-0.19%)Updated
Today's Range
₹990.00
₹1009.85
₹996.35
52 Week Range
52W Low₹636.10
52W High₹1004.70
₹996.35
Downside56.63%
Upside0.84%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹19,680.38 Cr
Market Cap
Total market value of companyP/E Ratio
58.40
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
7.96
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹15.47
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
7.83%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
14.00%
ROCE
Return on Capital Employed. >15% is goodNet Margin
15.34%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
-%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
-%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
77.50%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
548.00%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.17
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹102.12
Book Value
Net asset value per shareDividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
34.90%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
5 points- •Remarkable quarterly profit growth of 548% and sales growth of 77.50%.
- •Low debt-to-equity ratio of 0.17 provides strong financial stability.
Weaknesses
5 points- •High P/E ratio of 80.12 suggests a significant premium valuation.
- •ROCE 14.00% and ROE 11.00% are relatively lower than peers.
Opportunities
5 points- •Positioned in Healthcare and Pharmaceuticals to capitalize on industry expansion.
- •As a new listing (2024-12-18), potential for increased market awareness.
Threats
4 points- •Faces stiff competition from larger, established pharmaceutical industry peers.
- •High beta of 1.54 indicates significant stock price volatility.
Segment-wise Financial Analysis
Financial Results
Balance Sheet
Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format
No Balance Sheet Data Available
Standalone annual data is not available for this symbol.
Try switching to Consolidated view.
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
Recent Insider Transactions
| Insider Name | Transaction Date | Filing Date | Total Shares | Change | Price | Action |
|---|---|---|---|---|---|---|
TUNER GHOSH | 21 Feb 2025 | 26 Feb 2025 | 5.04 L | 71,116 | ₹713.07 | SELL |
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹1047.17 | +₹50.82 | +5.10% |
| R3 | ₹1027.32 | +₹30.97 | +3.11% |
| R2 | ₹1018.58 | +₹22.23 | +2.23% |
| R1 | ₹1007.47 | +₹11.12 | +1.12% |
| PIVOT | ₹998.73 | 2.38 | 0.24% |
| CURRENT | ₹996.35 | - | - |
| S1 | ₹947.92 | -₹48.43 | -4.86% |
| S2 | ₹967.77 | -₹28.58 | -2.87% |
| S3 | ₹978.88 | -₹17.47 | -1.75% |
| S4 | ₹987.62 | -₹8.73 | -0.88% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume+11.4% vs avg
9.80L
(02 Mar 2026)Delivery %+0.7% vs avg
54.8%
(02 Mar 2026)Avg Volume (20D)20-day average
8.80L
(03 Feb - 02 Mar)Avg Delivery %Trend ↑
54.1%
(03 Feb - 02 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Divis Laboratories Ltd
1.64L ₹ Cr
Best Profit Growth
OneSource Specialty Pharma Ltd
268.00 %
Highest Dividend Yield
Windlas Biotech Ltd
1.29 %
Peer Comparison
| Company Name |
|---|
 Akums Drugs & Pharmaceuticals Ltd |
 Anthem Biosciences Ltd |
 Dishman Carbogen Amcis Ltd |
 Divis Laboratories Ltd |
 Indegene Ltd |
 Innova Captab Ltd |
 OneSource Specialty Pharma Ltd |
 Suven Life Sciences Ltd |
 Syngene International Ltd |
 Vimta Labs Ltd |
 Windlas Biotech Ltd |
About
Sai Life Sciences Ltd
Sai Life Sciences Limited is a prominent Contract Research, Development, and Manufacturing Organization (CRDMO) with a global reach, headquartered in Hyderabad, India. Established in 1999 (and formerly known as SAI Advantium Pharma Limited until 2006), the company provides a comprehensive suite of services across the entire drug development lifecycle, from initial research to final manufacturing.
The core business of Sai Life Sciences centers around offering a wide range of services to pharmaceutical and biotechnology companies. These services encompass crucial aspects of drug development and production. Their expertise lies in medicinal chemistry, a critical area for designing and synthesizing new drug molecules. They also possess significant capabilities in pharmacokinetics (PK), the study of how drugs are absorbed, distributed, metabolized, and excreted by the body, which is crucial for determining optimal dosage and safety profiles.
Furthermore, Sai Life Sciences plays a vital role in the manufacturing process, handling the large-scale production of active pharmaceutical ingredients (APIs) and other drug substances. This aspect is crucial for bringing new medicines to the market. In addition to manufacturing, the company offers contract development services, assisting clients with the intricate process of developing their drugs from the laboratory to commercial production. This includes process development, analytical method development and validation, and regulatory support.
In essence, Sai Life Sciences acts as a comprehensive partner for pharmaceutical and biotechnology firms, offering a one-stop solution for many of their research, development, and manufacturing needs. This integrated approach allows clients to streamline their operations, reduce costs, and accelerate the development and launch of new drugs. Their broad service offering and global presence position them as a key player in the contract research and manufacturing landscape.
COMPANY FACTS - SAILIFE
Registered Address
L4- 01 & 02, SLN, Terminus Survey, Survey no. 133,Gachibowli Miyapur, Gachibowli
Hyderabad
TELANGANA
IN
Tel: 914068156000
Website:https://www.sailife.com/
Investor Relations:http://www.sailife.com/investors/
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Life Sciences Tools & Services
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 3,401
IPO Date: 18/12/2024
MANAGEMENT - SAILIFE
Mr. Krishnam Kanumuri
Chief Executive Officer, Managing Director (Promoter)
Mr. Sivaramakrishnan Chittor
Chief Financial Officer
Mr. Kanumuri Raju
Whole-Time Director (Promoter)
Ms. Runa Karan
Company Secretary
Mr. Ramesh Iyer
Independent Director
Ms. Suchita Sharma
Independent Director
Mr. Rajagopal Tatta
Independent Director
Investor Questions Answered
Sai Life Sciences Ltd (SAILIFE) Stock FAQs
Get answers to the most common questions about Sai Life Sciences Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Sai Life Sciences Ltd (SAILIFE) is ₹996.35. Today, the stock has declined by ₹1.90 (0.19%), trading in a range of ₹990 to ₹1,009.85. The stock opened at ₹992.5 with a trading volume of 9,80,255 shares.
Sai Life Sciences Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹19,680.38 crores, P/E ratio of 58.40, ROE of 7.83%, and ROCE of 14.00%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Sai Life Sciences Ltd (SAILIFE) is ₹1,004.7, while the 52-week low is ₹636.1. Currently trading at ₹996.35, the stock is 97.7% away from its 52-week low and 0.8% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Sai Life Sciences Ltd stock at ₹996.35 depends on multiple factors. The stock is currently trading with a P/E ratio of 58.40 and P/B ratio of N/A. Today's performance shows a loss of 0.19%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Sai Life Sciences Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹996.35, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Sai Life Sciences Ltd's key financial metrics include: P/E Ratio: 58.40, P/B Ratio: N/A, ROE: 7.83%, ROCE: 14.00%, Dividend Yield: 0.00%, EPS: ₹15.47, Book Value: ₹102.12, Debt-to-Equity: 0.17, and Current Ratio: N/A. The company's market cap stands at ₹19,680.38 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Sai Life Sciences Ltd stock opened at ₹992.5 and is currently trading at ₹996.35, showing a decline of ₹1.90 (0.19%). The intraday high is ₹1,009.85 and low is ₹990. The trading volume stands at 9,80,255 shares, indicating moderate market participation today.
Sai Life Sciences Ltd has a Price-to-Earnings (P/E) ratio of 58.40, which means investors are willing to pay ₹58.40 for every ₹1 of earnings. With an EPS of ₹15.47, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Sai Life Sciences Ltd has a market capitalization of ₹19,680.38 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹996.35) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Sai Life Sciences Ltd has a book value of ₹102.12 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹996.35, which is 875.7% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Sai Life Sciences Ltd has a Return on Equity (ROE) of 7.83% and Return on Capital Employed (ROCE) of 14.00%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Sai Life Sciences Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Sai Life Sciences Ltd has a debt-to-equity ratio of 0.17, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Sai Life Sciences Ltd has an Earnings Per Share (EPS) of ₹15.47, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹996.35 and P/E ratio of 58.40, investors are paying 58.40 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Sai Life Sciences Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Sai Life Sciences Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Sai Life Sciences Ltd stock, consider: 1) Fundamental Analysis - Review P/E (58.40), ROE (7.83%), debt-to-equity (0.17), and growth rates. 2) Technical Analysis - Check 52-week range (₹636.10 - ₹1004.70), moving averages, and chart patterns. 3) Valuation - Compare current price (₹996.35) with book value (₹102.12) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Sai Life Sciences Ltd share is ₹1.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹996.35 is 99535x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Sai Life Sciences Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹636.10 - ₹1004.70). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.17 indicates leverage. 4) Liquidity Risk - Based on trading volume of 9,80,255 shares. 5) Valuation Risk - P/E of 58.40 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Sai Life Sciences Ltd operates in the industry with key metrics: P/E ratio of 58.40, ROE of 7.83%, market cap of ₹19,680.38 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.17), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Sai Life Sciences Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹996.35, with a 52-week range of ₹636.10 to ₹1004.70. Based on fundamentals like P/E (58.40), ROE (7.83%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Sai Life Sciences Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹996.35. 2) Fundamental Deterioration - Declining ROE (currently 7.83%), increasing debt (D/E: 0.17), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Sai Life Sciences Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu